Omacor and omega-3 fatty acids for treatment of coronary artery disease and the pleiotropic effects

American Journal of Therapeutics

Volumn 21, Issue 1, 2014, Pages 56-66

  Kar, Subrata ^a  

^a UNIVERSITY OF MISSOURI   (United States)

Author keywords

arrhythmias; coronary artery disease; heart failure; omega 3 fatty acids

Indexed keywords

ANTI-ARRHYTHMIA AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ATHEROSCLEROSIS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CLINICAL TRIALS AS TOPIC; CORONARY ARTERY DISEASE; DOCOSAHEXAENOIC ACIDS; DRUG COMBINATIONS; EICOSAPENTAENOIC ACID; FATTY ACIDS, OMEGA-3; HEART FAILURE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS;

EID: 84894089291     PISSN: 10752765     EISSN: 15363686     Source Type: Journal    
DOI: 10.1097/MJT.0b013e31822b5603     Document Type: Article

References (52)

1. Psota TL, Gebauer SK, Kris-Etherton P. Dietary omega-3 fatty acid intake and cardiovascular risk. Am J Cardiol. 2006;98:3i-18i.
2. Jacobson TA. Secondary prevention of coronary artery disease with omega-3 fatty acids. Am J Cardiol. 2006;98: 61i-70i.
3. Weitz D, Weintraub H, Fisher E, et al. Fish oil for the treatment of cardiovascular disease. Cardiol Rev. 2010;18: 258-263.
4. Dimitrow PP, Jawien M. Pleiotropic, cardioprotective effects of omega-3 polyunsaturated fatty acids. Mini Rev Med Chem 2009;9:1030-1039.
5. Leaf A. On the reanalysis of the GISSI-Prevenzione. Circulation. 2002;105:1874-1875.
6. Robinson JG, Stone NJ. Antiatherosclerotic and antithrombotic effects of omega-3 fatty acids. Am J Cardiol. 2006; 98:39i-49i.
7. Saremi A, Arora R. The utility of omega-3 fatty acids in cardiovascular disease. Am J Ther. 2009;16:421-436.
8. Lee JH, O?Keefe JH, Lavie CJ, et al. Omega-3 fatty acids: Cardiovascular benefits, sources and sustainability. Nature reviews. Cardiology. 2009;6:753-758.
9. Lavie CJ, Milani RV, Mehra MR, et al. Omega-3 polyunsaturated fatty acids and cardiovascular diseases. J Am Coll Cardiol. 2009;54:585-594.
10. Richardson ES, Iaizzo PA, Xiao YF. Electrophysiological mechanisms of the anti-arrhythmic effects of omega-3 fatty acids. J Cardiovasc Transl Res. 2011;4:42-52.
11. Bays H. Clinical overview of Omacor: A concentrated formulation of omega-3 polyunsaturated fatty acids. Am J Cardiol. 2006;98:71i-76i.
12. Omega-3 polyunsaturated fatty acids (Omacor) for hypertriglyceridemia. Med Lett Drugs Ther. 2005;47:91.
13. Eckel RH. The fish oil story remains fishy. Circulation. 2010;122:2110-2112.
14. Marchioli R, Schweiger C, Tavazzi L, et al. Efficacy of n-3 polyunsaturated fatty acids after myocardial infarction: Results of GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell?Infarto Miocardico. Lipids. 2001;36(Suppl):S119-126.
15. Roth EM, Harris WS. Fish oil for primary and secondary prevention of coronary heart disease. Curr Atheroscler Rep. 2010;12:66-72.
16. Lavie CJ, Milani RV, Mehra MR, et al. Omega-3 polyunsaturated fatty acids and cardiovascular diseases. J Am Coll Cardiol. 2009;54:585-594.
17. Calabresi L, Donati D, Pazzucconi F, et al. Omacor in familial combined hyperlipidemia: Effects on lipids and low density lipoprotein subclasses. Atherosclerosis. 2000;148:387-396.
18. Nambi V, Ballantyne CM. Combination therapy with statins and omega-3 fatty acids. Am J Cardiol. 2006;98:34i-38i.
19. Kar S, Chockalingam A. Statin-associated rhabdomyolysis with acute renal failure complicated by intradialytic NSTEMI: A review of lipid management considerations. Am J Ther 2010 Dec 29 [Epub ahead of print].
20. Rupp H. Omacor (prescription omega-3-acid ethyl esters 90): From severe rhythm disorders to hypertriglyceridemia. Adv Ther. 2009;26:675-690.
21. Harper CR, Jacobson TA. Usefulness of omega-3 fatty acids and the prevention of coronary heart disease. Am J Cardiol. 2005;96:1521-1529.
22. Saravanan P, Davidson NC, Schmidt EB, et al. Cardiovascular effects of marine omega-3 fatty acids. Lancet. 2010;376:540-550.
23. CawoodAL, Ding R, Napper FL, et al. Eicosapentaenoic acid (EPA) from highly concentrated n-3 fatty acid ethyl esters is incorporated into advanced atherosclerotic plaques and higher plaque EPA is associated with decreased plaque inflammation and increased stability. Atherosclerosis. 2010;212:252-259.
24. Lee KW, Blann AD, Lip GY. Effects of omega-3 polyunsaturated fatty acids on plasma indices of thrombogenesis and inflammation in patients post-myocardial infarction. Thromb Res. 2006;118:305-312.
25. Stalenhoef AF, De Graaf J, Wittekoek ME, et al. The effect of concentrated n-3 fatty acids versus gemfibrozil on plasma lipoproteins, low density lipoprotein heterogeneity and oxidizability in patients with hypertriglyceridemia. Atherosclerosis. 2000;153:129-138.
26. Zampelas A. Eicosapentaenoic acid (EPA) from highly concentrated n-3 fatty acid ethyl esters is incorporated into advanced atherosclerotic plaques and higher plaque EPA is associated with decreased plaque inflammation and increased stability. Atherosclerosis. 2010; 212:34-35.
27. McGowan MP, Proulx S. Nutritional supplements and serum lipids: Does anything work Curr Atherosclerosis Rep. 2009;11:470-476.
28. Harris WS, Lu G, Rambjor GS, et al. Influence of n-3 fatty acid supplementation on the endogenous activities of plasma lipases. Am J Clin Nutr. 1997;66:254-260.
29. Marchioli R, Silletta MG, Levantesi G, et al. Omega-3 fatty acids and heart failure. Curr Atherosclerosis Rep. 2009;11: 440-447.
30. Von Schacky C. Omega-3 fatty acids and cardiovascular disease. Curr Opin Clin Nutr Metab Care. 2007;10:129-135.
31. Reiffel JA, Naccarelli GV. Antiarrhythmic drug therapy for atrial fibrillation: Are the guidelines guiding clinical practice Clin Cardiol. 2006;29:97-102.
32. Singer P, Wirth M. Can n-3 PUFA reduce cardiac arrhythmias Results of a clinical trial. Prostaglandins Leukot Essent Fatty Acids. 2004;71:153-159.
33. Pratt CM, Reiffel JA, Ellenbogen KA, et al. Efficacy and safety of prescription omega-3-acid ethyl esters for the prevention of recurrent symptomatic atrial fibrillation: A prospective study. Am Heart J. 2009;158:163-169.e1-3.
34. Kowey PR, Reiffel JA, Ellenbogen KA, et al. Efficacy and safety of prescription omega=3 fatty acids for the prevention of recurrent symptomatic atrial fibrillation: A randomized controlled trial. JAMA. 2010;304: 2363-2372.
35. Marchioli R, Barzi F, Bomba E, et al. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: Time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell?Infarto Miocardico (GISSI)-Prevenzione. Circulation. 2002;105:1897-1903.
36. Finzi AA, Latini R, Barlera S, et al. Effects of n-3 polyunsaturated fatty acids on malignant ventricular arrhythmias in patients with chronic heart failure and implantable cardioverter-defibrillators: A substudy of the Gruppo Italiano per lo Studio della Sopravvivenza nell?Insufficienza Cardiaca (GISSI-HF) trial. Am Heart J. 2011;161:338-343.e1.
37. Zhao YT, Chen Q, Sun YX, et al. Prevention of sudden cardiac death with omega-3 fatty acids in patients with coronary heart disease: A meta-analysis of randomized controlled trials. Ann Med. 2009;41:301-310.
38. Brouwer IA, Zock PL, Camm AJ, et al. Effect of fish oil on ventricular tachyarrhythmia and death in patients with implantable cardioverter defibrillators: The Study on Omega-3 Fatty Acids and Ventricular Arrhythmia (SOFA) randomized trial. JAMA. 2006;295: 2613-2619.
39. Burr ML, Ashfield-Watt PA, Dunstan FD, et al. Lack of benefit of dietary advice to men with angina: Results of a controlled trial. Eur J Clin Nutr. 2003;57:193-200.
40. Tavazzi L, Maggioni AP, Marchioli R, et al. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): A randomised, double-blind, placebo-controlled trial. Lancet. 2008;372:1223-1230.
41. Tavazzi L, Maggioni AP, Marchioli R, et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): A randomised, double-blind, placebocontrolled trial. Lancet. 2008;372:1231-1239.
42. Marchioli R, Levantesi G, Silletta MG, et al. Effect of n-3 polyunsaturated fatty acids and rosuvastatin in patients with heart failure: Results of the GISSI-HF trial. Exp Rev Cardiovasc Ther. 2009;7:735-748.
43. Mozaffarian D, Bryson CL, Lemaitre RN, et al. Fish intake and risk of incident heart failure. J Am Coll Cardiol. o 2005; 45:2015-2021.
44. Durrington PN, Bhatnagar D, Mackness MI, et al. An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemia. Heart. 2001;85:544-548.
45. Davidson MH, Stein EA, Bays HE, et al. Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: An 8-week, randomized, double-blind, placebocontrolled study. Clin Ther. 2007;29:1354-1367.
46. Burr ML, Fehily AM, Gilbert JF, et al. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: Diet and reinfarction trial (DART). Lancet. 1989;2:757-761.
47. Yokoyama M, Origasa H, Matsuzaki M, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): A randomised open-label, blinded endpoint analysis. Lancet. 2007;369: 1090-1098.
48. Rauch B, Schiele R, Schneider S, et al. OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction. Circulation. 2010;122:2152-2159.
49. Galan P, Kesse-Guyot E, Czernichow S, et al. Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: A randomised placebo controlled trial. BMJ. 2010;341:c6273.
50. Kromhout D, Giltay EJ, Geleijnse JM. n-3 fatty acids and cardiovascular events after myocardial infarction. N Engl J Med. 2010;363:2015-2026.
51. Farzaneh-Far R, Harris WS, Garg S, et al. Inverse association of erythrocyte n-3 fatty acid levels with inflammatory biomarkers in patients with stable coronary artery disease: The Heart and Soul Study. Atherosclerosis. 2009;205:538-543.
52. Filion KB, El Khoury F, Bielinski M, et al. Omega-3 fatty acids in high-risk cardiovascular patients: A meta-analysis of randomized controlled trials. BMC Cardiovasc Disord. 2010;10:24.